STALICLA

STALICLA is a clinical Stage Biotech Company developing a first in class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDDs). The company’s First focus of development has been Autism Spectrum Disorder (ASD). In its Geneva and Barcelona units, STALICLA has assembled a world class team of experienced drug developers and computational biologists. The company is recognized as a disruptive key player in the NDD space, using its DEPIv3 inn... ovative systems biology AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments. It is the first time that such technologies have been utilized within the field of neurodevelopmental disorders with the potential to change the direction of the specialty. In less than 3 years, the STALICLA platform has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identified two additional subgroups. STALICLA’s first ASD precision therapeutic - STP1- will be entering clinical trials mid 2020 in the United-States.